Charles River Laboratories
Charles River Laboratories International, Inc., commonly known as Charles River, is a leading provider of essential products and services for the pharmaceutical and biotechnology industries. Headquartered in the United States, the company operates extensively across North America, Europe, and Asia, offering a global reach that enhances its service delivery. Founded in 1947, Charles River has achieved significant milestones, including the expansion of its preclinical and clinical services. The company specialises in drug discovery, safety assessment, and laboratory services, providing unique solutions that streamline the research process. Its commitment to innovation and quality has solidified its position as a trusted partner in the life sciences sector. With a robust portfolio that includes in vivo and in vitro testing, Charles River Laboratories is recognised for its expertise and reliability, making it a preferred choice for organisations seeking to advance their research and development efforts.
DitchCarbon Score
How does Charles River Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Charles River Laboratories's score of 59 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Charles River Laboratories's reported carbon emissions
In 2023, Charles River Laboratories reported total greenhouse gas emissions of approximately 435,589,000 kg CO2e, with emissions distributed across all three scopes: 85,723,000 kg CO2e (Scope 1), 18,031,000 kg CO2e (Scope 2), and 435,589,000 kg CO2e (Scope 3). This represents a slight decrease in Scope 1 emissions from 90,002,000 kg CO2e in 2022, while Scope 2 emissions decreased from 45,976,000 kg CO2e in the same year. The company has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 50% by 2030, using 2018 as the baseline year. Additionally, Charles River Laboratories plans to reduce Scope 3 emissions by 15% by 2030, compared to a 2019 baseline. The company is also committed to increasing its annual sourcing of renewable electricity from 1% in 2018 to 100% by 2030. These targets align with industry standards for climate action, reflecting a commitment to significant emissions reductions in line with the goals of the Paris Agreement. Charles River Laboratories is actively working towards these objectives, demonstrating a proactive approach to sustainability in the pharmaceuticals and biotechnology sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,284,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 79,271,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Charles River Laboratories is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
